Ojjaara (momelotinib) approved in Canada for the treatment of ...
2 days ago · Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who have moderate to severe anemia and other key manifestations associated ...
FDA Approves GSK Myelofibrosis Med That Has Edge Over ... - MedCity News
Sep 17, 2023 · Ojjaara is a once-a-day oral small molecule designed to block two JAK proteins whose dysregulated signaling drives myelofibrosis progression. The drug also blocks another protein, A...
Health Canada approves GSK's Ojjaara for myelofibrosis in …
1 day ago · November 13, 2024. GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is indicated ...
Ojjaara (momelotinib) approved in the US as the first and only ...
Sep 15, 2023 · Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. To date, it is the only approved medicine for both newly diagnosed and previously treated...
In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara …
Sep 15, 2023 · After a delay to review additional data, the FDA has approved GSK’s momelotinib, now branded Ojjaara, to treat intermediate- or high-risk myelofibrosis in patients with anemia. In a pleasant ...
Ojjaara (momelotinib) approved in Canada for the treatment of ...
2 days ago · Ojjaara is the only once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. x The approval of Ojjaara by Health Canada is supported by data from the pivotal MOMENTUM Phase III ...
FDA approves GSK’s new bone cancer drug, helping validate a …
Sep 18, 2023 · GSK, which acquired momelotinib through the nearly $2 billion purchase of Sierra Oncology last year, plans to sell the drug under the brand name Ojjaara. GSK has said it sees “significant growth potential” in Ojjaara, though some analysts have questioned how impactful the drug will be to rival therapies sold by Incyte and Bristol Myers Squibb.
FDA approves GSK's Ojjaara for treatment of myelofibrosis …
Sep 18, 2023 · The FDA has approved Ojjaara, a drug developed by GSK plc (LSE:GSK), for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia, the pharmaceutical company announced on...
GSK gets wide FDA approval for myelofibrosis drug
Nov 8, 2024 · Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting...
FDA approves GSK’s Ojjaara for treating myelofibrosis patients …
Sep 18, 2023 · Ojjaara is a once-daily Janus kinase (JAK)1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor initially developed by Sierra Oncology. Ojjaara was included in GSK’s portfolio after the acquisition of Sierra in 2022. Myelofibrosis is a rare blood cancer that is characterised by the build-up of scar tissue (fibrosis) in the bone marrow.